S7 Ep32: Patel Provides Insight Into Post-Transplant Complications in Myeloid Disorders
Dr Patel discusses post-transplant complications in myeloid disorders, the prevalence of these complications, and the most common ones that may arise, including primary disease relapse, graft-vs-host disease, infection, organ toxicity, persistent cytopenias, and immunosuppression.
16m Sep 22, 2022
16m
S7 Ep31: FDA Approval Insights: Pemigatinib in FGFR1-Rearranged Myeloid/Lymphoid Neoplasms
Dr Verstovsek discusses the FDA approval of pemigatinib in myeloid/lymphoid neoplasms with FGFR1 rearrangements, the transformative effects of pemigatinib, and the importance of identifying chromosomal abnormalities in patients with this aggressive disease.
10m Sep 19, 2022
10m
S7 Ep30: Leal Sheds Light on Symptoms and Treatment of Lambert-Eaton Myasthenic Syndrome
Dr Leal discusses the symptoms commonly associated with Lambert-Eaton Myasthenic Syndrome, the prevalence of this disorder in concurrence with underlying cancers, and how amifampridine can help manage this disease by improving motor and autonomic symptoms.
14m Sep 15, 2022
14m
S7 Ep29: Elamin Elaborates on Poziotinib in EGFR Exon 20–Mutant NSCLC
Dr Elamin discusses results from a phase 2 study of poziotinib efficacy in EGFR exon 20–mutant non–small cell lung cancer and highlights the agent’s sensitivity in relation to insertion location.
11m Sep 12, 2022
11m
S7 Ep28: Chen Discusses Diagnosis, Management, and Disparities in Cutaneous T-cell Lymphoma
Dr Chen details the findings from a study of patients with transformed cutaneous T-cell lymphoma, gives her perspective on findings from the FLASH trial, and discusses the need for more research funding in cutaneous T-cell lymphoma.
19m Sep 08, 2022
19m
S7 Ep27: FDA Approval Insights: Trastuzumab Deruxtecan in HER2-Low Unresectable or Metastatic Breast Cancer
Dr Modi discusses the significance of the FDA approval of trastuzumab deruxtecan in metastatic HER2-low breast cancer, pivotal efficacy and safety data from the DESTINY-Breast04 trial, and how these findings pave the way for further progress across cancer therapy.
12m Sep 05, 2022
12m
S7 Ep27: Iams and Shah Break Down Lambert-Eaton Myasthenic Syndrome in SCLC and Other Neuroendocrine Cancers
Drs Iams and Shah discuss the process of diagnosing Lambert-Eaton myasthenic syndrome in neuroendocrine cancers, how the condition affects patient prognoses, and the primary goals of delivering coordinated care with in combination with cancer treatments.
20m Sep 01, 2022
20m
S7 Ep26: Bekaii-Saab, George, and von Mehren Discuss Pivotal Findings in GIST, TGCT, and RAS/RAF–Mutated Solid Tumors
Drs Bekaii-Saab, George, and von Mehren discuss key efficacy data and patient-reported outcomes from the INTRIGUE trial, the rationale for a phase 1/2 study investigating the novel ULK inhibitor DCC-3116 in patients with advanced or metastatic RAS or RAF–mutated solid tumors, and how vimiseltinib may alleviate unmet needs in the tenosynovial giant cell tumors population.
25m Aug 29, 2022
25m
S7 Ep25: FDA Approval Insights: Trastuzumab Deruxtecan in HER2-Mutant NSCLC
Dr Levy discusses the significance of the FDA approval of trastuzumab deruxtecan in HER2-mutant NSCLC, the pivotal efficacy and safety data from the DESTINY-Lung02 trial, and the optimal use of companion diagnostic tests in the field.
11m Aug 25, 2022
11m
S7 Ep24: Petrylak Provides Insight Into Testing, Multidisciplinary Management in Prostate and Bladder Cancer
Dr Petrylak discusses current issues with genetic testing and disease management in prostate and bladder cancer, some of the reasons for poor testing rates, and the importance of proper multidisciplinary management during testing and when seeking to mitigate adverse effects.
12m Aug 22, 2022
12m
S7 Ep24: Goldberg and Sussman Dissect Disparities in Gastric Cancer Mortality Rates
Drs Goldberg and Sussman discuss key findings from their research on rates of gastrointestinal mortality, the factors that could contribute to these differences, and ways these disparities can be addressed.
20m Aug 18, 2022
20m
S7 Ep23: FDA Approval Insights: Darolutamide Plus Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer
Dr Berchuck discusses the effects of treatment intensification with darolutamide in men with metastatic hormone-sensitive prostate cancer, the significance of the approval of darolutamide plus docetaxel and androgen deprivation therapy, and lingering questions left unanswered by the pivotal ARASENS study.
14m Aug 15, 2022
14m
S7 Ep22: Katz Considers the Role of Neoadjuvant Chemoradiation in Borderline Resectable Pancreatic Cancer
Dr Katz discusses the implications of a recently published phase 2 study investigating neoadjuvant mFOLFIRINOX with or without hypofractionated radiation therapy results for patients with borderline resectable pancreatic ductal adenocarcinoma.
17m Aug 11, 2022
17m
S7 Ep21: Leukemia Experts Reflect on Defining Moments as Women in the Field
Drs Luger, Roboz, and Stock discuss the issues that were most prominent in leukemia treatment when they began their careers and what motivated them to continue to work toward progress in the field even when treatment outcomes were dismal. They also share their experiences with being women in their chosen career paths, such as how their gender has influenced their professional and personal decis...
1hr 2m Aug 08, 2022
1hr 2m
S7 Ep20: Gradishar Stresses the Importance of Accurately Defining Breast Cancer Subtypes
Dr Gradishar emphasizes the importance of defining metastatic breast cancer subtypes, the implications of molecular testing and genetics on treatment decisions, and the need for honest and comprehensive patient-provider communication about therapeutic options and clinical trial opportunities throughout the course of disease.
16m Aug 04, 2022
16m
S7 Ep19: Research Reflections: Subbiah Reviews Striking ASCO 2022 Data Across Oncology
Dr Subbiah discusses findings from 4 presentations that stood out to him from the 2022 ASCO Annual Meeting: phase 2 data (NCT04165772) demonstrating a 100% complete response rate in 12 patients with mismatch repair–deficient, locally advanced rectal cancer who received dostarlimab (Jemperli); DESTINY-Breast04 (NCT03734029), results he called “important and practice changing” for patients with H...
12m Aug 01, 2022
12m
S7 Ep18: FDA Approval Insights: Liso-Cel in Second-Line Relapsed/Refractory LBCL
Dr Ghosh discusses the FDA approval of lisocabtagene maraleucel in large B-cell lymphoma, pivotal efficacy and safety data from the phase 3 TRANSFORM trial (NCT03575351) and the phase 2 TRANSCEND-PILOT-017006 study (NCT03483103), and the effect of the approval on academic and community center practice patterns.
20m Jul 28, 2022
20m
S7 Ep17: Wagner Weighs In On Research and Development in Angiosarcoma
Dr Wagner talks about the struggle to investigate angiosarcoma, the ways research cooperatives have had recent success in driving the science forward, and the potential for immunotherapy in this disease.
25m Jul 25, 2022
25m
S7 Ep16: FDA Approval Insights: Dabrafenib Plus Trametinib for BRAF V600E–Mutated Unresectable or Metastatic Solid Tumors
Dr Subbiah highlights the significance of the FDA approval of dabrafenib and trametinib in adult and pediatric patients at least 6 years of age with BRAF V600E–mutant metastatic or unresectable solid tumors and contextualizes the pivotal data for rare tumor types.
14m Jul 21, 2022
14m
S7 Ep15: Monk Recaps Benefit of Rucaparib Maintenance Therapy in Advanced Ovarian Cancer
Dr Monk discusses pertinent efficacy and safety data from the ATHENA-MONO trial, which evaluated first-line maintenance treatment with rucaparib in patients with stage III-IV high-grade ovarian cancer.
8m Jul 18, 2022
8m
S7 Ep14: Jain Discusses the Driving Forces of Gender Inequities in Medicine
Dr Jain discusses an article she authored, titled “We’re Running Up the Wrong Side of the Escalator,” which confronts systemic and structural obstacles facing women in medicine.
31m Jul 14, 2022
31m
S7 Ep13: Spiess Shares the Importance of Comprehensive, Multidisciplinary Care in Penile Cancer
Dr Spiess talks about taking part in an international consortium that seeks to establish a standard treatment for penile cancer, the ways shame interferes with diagnosis and treatment, and the complicated issues of gender and sexuality involved with this disease.
18m Jul 11, 2022
18m
S7 Ep12: Research Reflections: Tarantino Talks Through the Implications of ASCO 2022 Data in Breast Cancer
Dr Tarantino discusses practice-changing findings in breast cancer and emphasizes the ways in which positive study data can improve the breast cancer treatment paradigm going forward.
23m Jul 07, 2022
23m
S7 Ep11: Duma Discusses the Unique Challenges of Women With Lung Cancer (Continued)
Dr Duma discusses improving diversity in trials and in oncology providers, how the oncology field fails women in general and women of color in particular, and the stress lung cancer puts on a woman’s home life.
24m Jul 04, 2022
24m
S7 Ep10: Duma Discusses the Unique Challenges of Women With Lung Cancer
Dr Duma discusses the leading causes of lung cancer in women, the ongoing failure to screen a sufficient number of women for lung cancer, and how gender bias interferes with treatment.
20m Jun 30, 2022
20m
S7 Ep9: Leukemia Pioneers Chronicle Career Experiences and Milestones
Drs Karp, Raza, and Le Beau discuss challenges they faced in their early careers as women in leukemia, the ways they overcame those obstacles, and the unique pitfalls and successes they’ve experienced as female physicians.
58m Jun 27, 2022
58m
S7 Ep8: Khan Casts Light on Disparities in Surgical Care of GI Tract Cancer
Dr Khan expands on key data found on racial disparities in surgical outcomes for gastrointestinal tract cancer and addresses the need to reduce the gap in these outcomes.
13m Jun 23, 2022
13m
S7 Ep7: Wise Summarizes Survival Data From ARASENS and PEACE-1 in Prostate Cancer
Dr Wise highlights how intensified treatment with doublet or triplet therapy can lead to better long-term outcomes in prostate cancer, potential treatment sequencing options, and the importance of communication between patients and physicians.
19m Jun 20, 2022
19m
S7 Ep6: Lee Lays Out Treatment Developments in Non–Clear Cell RCC
Dr Lee highlights the latest treatment developments in non–clear cell renal cell carcinoma, emphasizes the need for more precise classification of the histologic subsets of this disease, and discusses the investigation of cabozantinib plus nivolumab across stratified cohorts of non–clear cell renal cell carcinoma.
16m Jun 16, 2022
16m
S7 Ep5: Ueno Underscores the Importance of Accurate Diagnoses and Novel Treatments in IBC
Dr Ueno discusses the challenges of diagnosing inflammatory breast cancer, the unmet need for new agents to treat patients with the disease, and the current ongoing research he’s eager to see reported.
14m Jun 13, 2022
14m
S7 Ep4: Hua Highlights Innovative Research With Immunotherapy in NETs
Dr Hua talks about the unmet need in neuroendocrine tumors (NETs), explains the difficulty of detecting NETs, and highlights his study findings evaluating anti-CDH17 CAR T cells in this disease.
15m Jun 09, 2022
15m
S7 Ep3: Jefferson Faculty Highlight COVID-19-Induced Disparities in Older Patients With Cancer
Chapman, Swartz, Rhodes, Nightingale, and Denton highlight the evolution of Jefferson Health’s Senior Adult Oncology Center, the unique needs of older adults who develop cancer, and challenges stemming from the COVID-19 pandemic that have affected the care of geriatric patients with cancer, such as the strain put on caregivers and the shift to telemedicine.
27m Jun 06, 2022
27m
S7 Ep2: Abid Accounts for the Efficacy of a Third SARS-CoV-2 Vaccine Among Transplant, CAR T-Cell, and BiTE Recipients
Dr Abid discusses a review paper, published in Cancer Cell, that evaluated determinants of response to SARS-CoV-2 vaccines in patients who underwent allogeneic or autologous hematopoietic cell transplantation or who had received CAR T-cell therapy or bispecific T-cell engagers.
20m Jun 02, 2022
20m
S7 Ep1: Karmanos Faculty Share Experiences and Career Insights as Women in Oncology
Drs Mamdani, Assad, and Robinette discuss the changes in the culture of oncology today compared with when they first started their careers, the challenges they experienced along the way, and advice they would share with up-and-coming oncologists based on what they know now.
19m May 30, 2022
19m
S6 Ep50: Tarantino Previews Exciting Research in HER2-Low Breast Cancer
Dr Tarantino provides background on the categorization of HER2-low disease in breast cancer, issues with standardization and interpretation, historical management strategies, and ongoing research with agents including trastuzumab deruxtecan, trastuzumab duocarmazine, and disitamab vedotin.
17m May 26, 2022
17m
S6 Ep49: Taylor Provides Insight Into Pirtobrutinib Resistance in CLL
Dr Taylor discusses the significance of BTK inhibition in chronic lymphocytic leukemia, describes the key objectives of, and methods used, for the genomic analyses performed by his team, underscores the clinical significance of the data yielded from this research, and outlines where future efforts will focus.
18m May 23, 2022
18m
S6 Ep48: Pro Presents Interim Results of PRIMO in Peripheral T-Cell Lymphoma
Dr Pro outlines the current role of duvelisib in peripheral T-cell lymphoma (PTCL), reviews some key adverse effects associated with the agent, and walks us through other important updates in PTCL presented at the 2021 ASH Annual Meeting and Exposition.
14m May 19, 2022
14m
S6 Ep47: Pal Discusses Eye-Catching ASCO GU Data in RCC
Dr Pal walks us through research presented at the 2022 Genitourinary Cancers Symposium, including data from the TIVO-3 trial (NCT02627963) and findings from the NeoAvAx trial (NCT03341845) exploring avelumab (Bavencio) plus axitinib (Inlyta) for patients with high-risk, nonmetastatic clear-cell renal cell carcinoma.
12m May 16, 2022
12m
S6 Ep46: Pegram Expounds on Exciting Developments in HER2+ Metastatic Breast Cancer
Dr Pegram discusses treatment sequencing in metastatic HER2-positive breast cancer, recent updates to the National Comprehensive Cancer Network guidelines, and the influence of the DESTINY-Breast03 trial on the breast cancer treatment paradigm.
14m May 12, 2022
14m
S6 Ep45: Cusnir on the Benefits of SIR-Spheres® Y-90 Resin Microspheres in mCRC
Dr Cusnir reviews the benefits of isolating the liver in early colorectal cancer (CRC) treatment, how patients have tolerated Y-90 therapy, and situations in which Y-90 therapy would be most effective for patients with CRC.
17m May 09, 2022
17m
S6 Ep44: Borgen Recommends Revamping Peer Review for a Post-COVID-19 World
Dr Borgen recaps a presentation he made at the 2022 Miami Breast Cancer Conference highlighting the flaws with preprints, outlining his recommendations for fixing peer review, and explaining how this affects cancer research. 
23m May 05, 2022
23m
S6 Ep43: FDA Approval Insights: Relatlimab Plus Nivolumab in Melanoma
Dr Lipson discusses the significance of the regulatory decision for relatlimab and nivolumab, updated data from the RELATIVITY-047 trial, adverse effects clinicians should be aware of when prescribing the doublet, and the potential next steps for this therapy in melanoma.
10m May 02, 2022
10m
S6 Ep42: Jabbour Highlights New Data With Asciminib and Ponatinib in CML
Dr Jabbour discusses updates from the 2021 ASH Annual Meeting and Exposition in chronic myeloid leukemia, including findings from the phase 3 ASCEMBL trial (NCT03106779) evaluating asciminib (Scemblix) vs bosutinib (Bosulif) and data with ponatinib (Iclusig) from a post hoc analysis of the phase 2 OPTIC trial (NCT02467270).
12m Apr 28, 2022
12m
S6 Ep41: Bardia Reflects on Important Data in HER2+ Breast Cancer
Dr Bardia discusses data from DESTINY-Breast03 (NCT03529110), HER2CLIMB (NCT02614794), and NALA (NCT01808573), important findings that were presented at the 2021 San Antonio Breast Cancer Symposium for patients who have HER2-positive metastatic breast cancer.
10m Apr 21, 2022
10m
S6 Ep40: D'Abreo Addresses AEs in Metastatic Breast Cancer Care
Dr D’Abreo discusses adverse effects such as fatigue, nausea and vomiting, and interstitial lung disease, shares advice on establishing an open channel of communication with patients, and highlights preventive and proactive management strategies for treatment-related adverse effects.
20m Apr 14, 2022
20m
S6 Ep39: Tripathy on Treating HER2+ Breast Cancer With Leptomeningeal Metastasis
Dr Tripathy explains the rationale for the TBCRC049 trial, the challenges of investigating a disease that appears in less than 5% of patients with breast cancer, and potential avenues for future investigations.
10m Apr 07, 2022
10m
S6 Ep38: FDA Approval Insights: Pacritinib in Myelofibrosis
Dr Mesa discusses the data that led to the FDA approval of pacritinib, toxicities clinicians should be aware of when prescribing the JAK inhibitor, and the next steps for pacritinib in the space.
13m Mar 31, 2022
13m
S6 Ep37: Research Reflections: Barzi Reviews CRC Updates From ASCO GI 2022
Dr Barzi discusses data from the ACCENT and RESPECT trials evaluating the value of oxaliplatin for patients with colorectal cancer, results from an investigation of nivolumab plus ipilimumab for patients with high tumor mutational burden, and more.
18m Mar 24, 2022
18m
S6 Ep36: Lyle and Patel Examine Diagnostic and Management Paradigms in MDS
Drs Lyle and Patel review some of the challenges associated with the diagnosis and management of myelodysplastic syndromes, the current treatment landscape, and the role of next-generation sequencing and optimal testing practices in the field.
18m Mar 17, 2022
18m
S6 Ep35: Ross Reflects on Surgical Advances and Changing Trends in CRC
Dr Ross shares his advice to health care professionals regarding the detection and treatment of patients with colon cancer, unmet needs for this patient population, the role of minimally invasive surgery, and the need to address and overcome health disparities that affect this population.
11m Mar 10, 2022
11m